N-methyl-4-(4-chlorophenyl)-2-oxazolepropionamide | 131806-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-methyl-4-(4-chlorophenyl)-2-oxazolepropionamide
• 英文别名: 3-[4-(4-chlorophenyl)-1,3-oxazol-2-yl]-N-methylpropanamide
• CAS: 131806-04-7
• 化学式: C₁₃H₁₃ClN₂O₂
• 分子量: 264.711
• InChiKey: MNNCYNIISNBLTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯甲酸乙酯 、 4-(4-chlorophenyl)-2-oxazolepropionic acid 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到N-methyl-4-(4-chlorophenyl)-2-oxazolepropionamide
  参考文献：
  名称：

  Oxazole compounds and their use as antidiabetic and bone-reduction

  摘要：

  噁唑化合物的化学式为：##STR1## 其中A是化学式为--CH.sub.2 OR.sup.3（R.sup.3是氢原子、可选择取代的碳氢残基、可选择取代的杂环基或酰基），或醛基，B是可选择取代的苯基，或其盐，它们可用作抗糖尿病药物。

  公开号：

  US05239080A1

文献信息

• Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
  申请人：sanofi-aventis

  公开号：EP1939181A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3具有索引中指示的含义，这些化合物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮一氧化氮合酶表达或治疗各种疾病的药物的用途，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Use of oxazole compounds to treat osteoporosis
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05371098A1

  公开（公告）日：1994-12-06

  An oxazole compound having the formula (I): ##STR1## in which A is a group of the formula --CH.sub.2 OR.sup.2 (wherein R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an acyl group) or an aldehyde group, B is an optionally substituted phenyl group, R.sup.1 is a hydrogen atom or an optionally substituted alkyl group, and n is an integer of 0 to 6, provided that when n is 2, R.sup.1 is an optionally substituted alkyl group, or its salt, which is useful as a therapeutic agent for metabolic bone diseases including osteoporosis.

  一种具有以下式子（I）的噁唑化合物： ##STR1## 其中A是式子--CH.sub.2 OR.sup.2的基团（其中R.sup.2是氢原子，可选择性取代的碳氢残基，可选择性取代的杂环基团或酰基），或者是醛基团；B是可选择性取代的苯基团；R.sup.1是氢原子或可选择性取代的烷基团；n是0到6的整数，但当n为2时，R.sup.1是可选择性取代的烷基团；以及其盐。该化合物可用作治疗代谢性骨疾病，包括骨质疏松症的治疗剂。
• HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016337A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3在权利要求中所示，它们调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体来说，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组成物，以及公式I化合物用于制造用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心力衰竭等。
• Oxazole compounds and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0382199A1

  公开（公告）日：1990-08-16

  Oxazole compounds having the formula: in which A is a group of the formula -CH₂OR³ (R³ is a hydrogen atom, an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an acyl group), or an aldehyde group and B is an optionally substituted phenyl group, or their salts, which are useful as antidiabetic agents.

  具有以下式子的噁唑化合物 其中 A 是式 -CH₂OR³ 的基团（R³ 是氢原子、任选取代的烃残基、任选取代的杂环基团或酰基）或醛基，B 是任选取代的苯基、 或它们的盐类，可用作抗糖尿病药物。
• Oxazole compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0440183A1

  公开（公告）日：1991-08-07

  An oxazole compound having the formula (I): in which A is a group of the formula -CH₂OR² (wherein R² is a hydrogen atom, an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an acyl group) or an aldehyde group, B is an optionally substituted phenyl group, R¹ is a hydrogen atom or an optionally substituted alkyl group, and n is an integer of 0 to 6, provided that when n is 2, R¹ is an optionally substituted alkyl group, or its salt, which is useful as a therapeutic agent for metabolic bone diseases including osteoporosis.

  一种具有式 (I) 的噁唑化合物： 其中 A 是式 -CH₂OR²（其中 R² 是氢原子、任选取代的烃残基、任选取代的杂环基团或酰基）或醛基团，B 是任选取代的苯基，R¹ 是氢原子或任选取代的烷基，n 是 0 至 6 的整数，但当 n 为 2 时，R¹ 是任选取代的烷基，该化合物或其盐可用作代谢性骨病（包括骨质疏松症）的治疗剂。